Clearpoint Neuro is trading 5.7% up at $14.15, reflecting broader healthcare strength and a rebound following its August 3 earnings selloff.
- Healthcare stocks are gaining 1.27% in pre-market trading.
- Second-quarter revenue was $10.9 million, but losses widened; 2026 guidance was reduced to $48 million–$52 million.
- Cash stood at $29.4 million, with no new company-specific announcement identified for August 7, 2026.